Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study

J. Gerry Coghlan, Richard Channick, Kelly Chin, Lilla Di Scala, Nazzareno Galiè, Hossein Ardeschir Ghofrani, Marius M. Hoeper, Irene M. Lang, Vallerie McLaughlin, Ralph Preiss, Lewis J. Rubin, Gérald Simonneau, Olivier Sitbon, Victor F. Tapson, Sean Gaine

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: In pulmonary arterial hypertension (PAH), combination therapy is an important treatment strategy. Although randomized controlled trial data are available to support the combination of two therapies, data regarding triple combination therapy are few. Objective: The phase III GRIPHON trial enrolled 1156 patients with PAH, including 376 receiving background double combination therapy. We evaluated the efficacy and safety of selexipag as a third agent in these patients and further analyzed this subgroup according to symptom burden at baseline as indicated by World Health Organization (WHO) functional class (FC). Methods: In this post hoc analysis, hazard ratios (HRs) and 95% confidence intervals (CI) were calculated using Cox proportional-hazard models to determine response to selexipag versus placebo on the composite primary endpoint of morbidity/mortality. Baseline characteristics and adverse events were summarized descriptively. Results: Of 376 patients receiving background endothelin receptor antagonist (ERA) and phosphodiesterase-5 inhibitor (PDE-5i) therapy, 115 had WHO FC II symptoms and 255 had WHO FC III symptoms at baseline. The impact on the primary endpoint of adding selexipag versus placebo to double combination therapy was consistent with the effect in the overall population (HR 0.63; 95% CI 0.44–0.90) as well as in patients with WHO FC II and III symptoms. Compared with the overall population, discontinuations due to an adverse event were higher when selexipag was added to background double combination therapy; no safety concerns were identified. Conclusion: The addition of selexipag to background double combination therapy with an ERA and PDE-5i provides an incremental benefit similar to that seen in the overall population, including in patients with WHO FC II or III symptoms at baseline. ClinicalTrials.gov Identifier: NCT01106014.

Original languageEnglish (US)
Pages (from-to)1-11
Number of pages11
JournalAmerican Journal of Cardiovascular Drugs
DOIs
StateAccepted/In press - Jan 6 2018

Fingerprint

Epoprostenol
Pulmonary Hypertension
Phosphodiesterase 5 Inhibitors
Therapeutics
Placebos
Confidence Intervals
Population
Safety
selexipag
Proxy
Proportional Hazards Models
Randomized Controlled Trials
Morbidity
Mortality

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Cite this

Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy : Insights from the Randomized Controlled GRIPHON Study. / Coghlan, J. Gerry; Channick, Richard; Chin, Kelly; Di Scala, Lilla; Galiè, Nazzareno; Ghofrani, Hossein Ardeschir; Hoeper, Marius M.; Lang, Irene M.; McLaughlin, Vallerie; Preiss, Ralph; Rubin, Lewis J.; Simonneau, Gérald; Sitbon, Olivier; Tapson, Victor F.; Gaine, Sean.

In: American Journal of Cardiovascular Drugs, 06.01.2018, p. 1-11.

Research output: Contribution to journalArticle

Coghlan, JG, Channick, R, Chin, K, Di Scala, L, Galiè, N, Ghofrani, HA, Hoeper, MM, Lang, IM, McLaughlin, V, Preiss, R, Rubin, LJ, Simonneau, G, Sitbon, O, Tapson, VF & Gaine, S 2018, 'Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study', American Journal of Cardiovascular Drugs, pp. 1-11. https://doi.org/10.1007/s40256-017-0262-z
Coghlan, J. Gerry ; Channick, Richard ; Chin, Kelly ; Di Scala, Lilla ; Galiè, Nazzareno ; Ghofrani, Hossein Ardeschir ; Hoeper, Marius M. ; Lang, Irene M. ; McLaughlin, Vallerie ; Preiss, Ralph ; Rubin, Lewis J. ; Simonneau, Gérald ; Sitbon, Olivier ; Tapson, Victor F. ; Gaine, Sean. / Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy : Insights from the Randomized Controlled GRIPHON Study. In: American Journal of Cardiovascular Drugs. 2018 ; pp. 1-11.
@article{2570cde36cf24a228313cfc5d2bf64f9,
title = "Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study",
abstract = "Background: In pulmonary arterial hypertension (PAH), combination therapy is an important treatment strategy. Although randomized controlled trial data are available to support the combination of two therapies, data regarding triple combination therapy are few. Objective: The phase III GRIPHON trial enrolled 1156 patients with PAH, including 376 receiving background double combination therapy. We evaluated the efficacy and safety of selexipag as a third agent in these patients and further analyzed this subgroup according to symptom burden at baseline as indicated by World Health Organization (WHO) functional class (FC). Methods: In this post hoc analysis, hazard ratios (HRs) and 95{\%} confidence intervals (CI) were calculated using Cox proportional-hazard models to determine response to selexipag versus placebo on the composite primary endpoint of morbidity/mortality. Baseline characteristics and adverse events were summarized descriptively. Results: Of 376 patients receiving background endothelin receptor antagonist (ERA) and phosphodiesterase-5 inhibitor (PDE-5i) therapy, 115 had WHO FC II symptoms and 255 had WHO FC III symptoms at baseline. The impact on the primary endpoint of adding selexipag versus placebo to double combination therapy was consistent with the effect in the overall population (HR 0.63; 95{\%} CI 0.44–0.90) as well as in patients with WHO FC II and III symptoms. Compared with the overall population, discontinuations due to an adverse event were higher when selexipag was added to background double combination therapy; no safety concerns were identified. Conclusion: The addition of selexipag to background double combination therapy with an ERA and PDE-5i provides an incremental benefit similar to that seen in the overall population, including in patients with WHO FC II or III symptoms at baseline. ClinicalTrials.gov Identifier: NCT01106014.",
author = "Coghlan, {J. Gerry} and Richard Channick and Kelly Chin and {Di Scala}, Lilla and Nazzareno Gali{\`e} and Ghofrani, {Hossein Ardeschir} and Hoeper, {Marius M.} and Lang, {Irene M.} and Vallerie McLaughlin and Ralph Preiss and Rubin, {Lewis J.} and G{\'e}rald Simonneau and Olivier Sitbon and Tapson, {Victor F.} and Sean Gaine",
year = "2018",
month = "1",
day = "6",
doi = "10.1007/s40256-017-0262-z",
language = "English (US)",
pages = "1--11",
journal = "American Journal of Cardiovascular Drugs",
issn = "1175-3277",
publisher = "Adis International Ltd",

}

TY - JOUR

T1 - Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy

T2 - Insights from the Randomized Controlled GRIPHON Study

AU - Coghlan, J. Gerry

AU - Channick, Richard

AU - Chin, Kelly

AU - Di Scala, Lilla

AU - Galiè, Nazzareno

AU - Ghofrani, Hossein Ardeschir

AU - Hoeper, Marius M.

AU - Lang, Irene M.

AU - McLaughlin, Vallerie

AU - Preiss, Ralph

AU - Rubin, Lewis J.

AU - Simonneau, Gérald

AU - Sitbon, Olivier

AU - Tapson, Victor F.

AU - Gaine, Sean

PY - 2018/1/6

Y1 - 2018/1/6

N2 - Background: In pulmonary arterial hypertension (PAH), combination therapy is an important treatment strategy. Although randomized controlled trial data are available to support the combination of two therapies, data regarding triple combination therapy are few. Objective: The phase III GRIPHON trial enrolled 1156 patients with PAH, including 376 receiving background double combination therapy. We evaluated the efficacy and safety of selexipag as a third agent in these patients and further analyzed this subgroup according to symptom burden at baseline as indicated by World Health Organization (WHO) functional class (FC). Methods: In this post hoc analysis, hazard ratios (HRs) and 95% confidence intervals (CI) were calculated using Cox proportional-hazard models to determine response to selexipag versus placebo on the composite primary endpoint of morbidity/mortality. Baseline characteristics and adverse events were summarized descriptively. Results: Of 376 patients receiving background endothelin receptor antagonist (ERA) and phosphodiesterase-5 inhibitor (PDE-5i) therapy, 115 had WHO FC II symptoms and 255 had WHO FC III symptoms at baseline. The impact on the primary endpoint of adding selexipag versus placebo to double combination therapy was consistent with the effect in the overall population (HR 0.63; 95% CI 0.44–0.90) as well as in patients with WHO FC II and III symptoms. Compared with the overall population, discontinuations due to an adverse event were higher when selexipag was added to background double combination therapy; no safety concerns were identified. Conclusion: The addition of selexipag to background double combination therapy with an ERA and PDE-5i provides an incremental benefit similar to that seen in the overall population, including in patients with WHO FC II or III symptoms at baseline. ClinicalTrials.gov Identifier: NCT01106014.

AB - Background: In pulmonary arterial hypertension (PAH), combination therapy is an important treatment strategy. Although randomized controlled trial data are available to support the combination of two therapies, data regarding triple combination therapy are few. Objective: The phase III GRIPHON trial enrolled 1156 patients with PAH, including 376 receiving background double combination therapy. We evaluated the efficacy and safety of selexipag as a third agent in these patients and further analyzed this subgroup according to symptom burden at baseline as indicated by World Health Organization (WHO) functional class (FC). Methods: In this post hoc analysis, hazard ratios (HRs) and 95% confidence intervals (CI) were calculated using Cox proportional-hazard models to determine response to selexipag versus placebo on the composite primary endpoint of morbidity/mortality. Baseline characteristics and adverse events were summarized descriptively. Results: Of 376 patients receiving background endothelin receptor antagonist (ERA) and phosphodiesterase-5 inhibitor (PDE-5i) therapy, 115 had WHO FC II symptoms and 255 had WHO FC III symptoms at baseline. The impact on the primary endpoint of adding selexipag versus placebo to double combination therapy was consistent with the effect in the overall population (HR 0.63; 95% CI 0.44–0.90) as well as in patients with WHO FC II and III symptoms. Compared with the overall population, discontinuations due to an adverse event were higher when selexipag was added to background double combination therapy; no safety concerns were identified. Conclusion: The addition of selexipag to background double combination therapy with an ERA and PDE-5i provides an incremental benefit similar to that seen in the overall population, including in patients with WHO FC II or III symptoms at baseline. ClinicalTrials.gov Identifier: NCT01106014.

UR - http://www.scopus.com/inward/record.url?scp=85040079654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040079654&partnerID=8YFLogxK

U2 - 10.1007/s40256-017-0262-z

DO - 10.1007/s40256-017-0262-z

M3 - Article

C2 - 29307087

AN - SCOPUS:85040079654

SP - 1

EP - 11

JO - American Journal of Cardiovascular Drugs

JF - American Journal of Cardiovascular Drugs

SN - 1175-3277

ER -